Piramal Pharma Limited (PPLPHARMA.NS)
INR 211.04
(-0.0%)
INR 211.04
(-0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.05 Billion INR | 31.79% |
| 2022 | 8.46 Billion INR | 121.3% |
| 2021 | 12.1 Billion INR | -32.91% |
| 2020 | 6.11 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.19 Billion INR | 87.47% |
| 2024 Q1 | 2.04 Billion INR | -57.39% |
| 2023 Q1 | 1.85 Billion INR | -51.76% |
| 2023 FY | - INR | 31.79% |
| 2023 Q4 | 5.29 Billion INR | 54.13% |
| 2023 Q3 | 3.43 Billion INR | 2.96% |
| 2023 Q2 | 3.33 Billion INR | 80.49% |
| 2022 Q1 | 1.08 Billion INR | 222.55% |
| 2022 FY | - INR | 121.3% |
| 2022 Q4 | 3.83 Billion INR | 106.83% |
| 2022 Q3 | 1.85 Billion INR | -19.33% |
| 2022 Q2 | 2.29 Billion INR | 111.24% |
| 2021 Q1 | 1.81 Billion INR | 0.0% |
| 2021 FY | - INR | -32.91% |
| 2021 Q4 | -888 Million INR | -122.46% |
| 2021 Q3 | 3.95 Billion INR | 71.28% |
| 2021 Q2 | 2.3 Billion INR | 27.09% |
| 2020 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 68.561% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | -469.533% |
| Concord Biotech Limited | 4.65 Billion INR | -180.212% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | -325.008% |
| Jubilant Ingrevia Limited | 4.56 Billion INR | -186.037% |
| Lyka Labs Limited | 167.58 Million INR | -7690.129% |
| Panacea Biotec Limited | -47.58 Million INR | 27538.84% |
| SMS Lifesciences India Limited | 349.41 Million INR | -3636.413% |
| Supriya Lifescience Limited | 1.83 Billion INR | -611.171% |
| Syngene International Limited | 10.84 Billion INR | -20.36% |
| TAKE Solutions Limited | -1.05 Billion INR | 1342.378% |
| Zota Health Care Limited | 82.07 Million INR | -15807.058% |